Kalvista Pharmaceuticals Inc KALV

$27.00 +0.01 (0.04%)

Valuation

Market cap
1,437,507,000
Revenue TTM
$49,080,000
Net income TTM
$-109,520,000
PE ratio
0.00
Forward PE
—
Profit margin
-223.15%
Debt to equity
0.00

Trading

Volume
4,272,700
Avg volume
4,070,578
Day's range
$26.98 – $27.00
Shares out
53,241,000
Stochastic %K
100%
Beta
-0.12
Analysts
Sell
Price target
$29.17

Price

Company profile

As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceutic...

Show more

As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.

Industry
Biotechnology
Sector
Healthcare
Phone
857 999 0075
Website
https://www.kalvista.com
Address
200 Crossing Boulevard, Framingham, United States

Latest news

Stocktwits

JFais Oct 23, 2:04 PM
$PHAR (L) Under the radar growth story in the rare disease space Encouraging rebound in Ruconest revenues, despite oral HAE competitors $BCRX $KALV $PHVS Joenja sales +58%, accelerating 2027-2028 via international launch +label expansion to younger patients (notes in Chat) *Caveat, very low trading volume
0 replies
JuggernautRaider Oct 11, 6:54 PM
Agreed Prop Joe! $TNXP $NUVB $KALV $ALLR ♋️ ☮️ PROMISES MADE: promises kept 🌎 💚 💊 ✌️
0 replies
Quantumup Aug 13, 5:07 PM
$PHVS Guggenheim⬆️to $40 vs $39; stays Buy BofA⬆️to $38 vs $35; stays Neutral RBC Capital⬆️to $52 vs $51; stays OP $KALV $BCRX IONS TAK Citizens⬆️to $75 vs $74; stays Outperform and said -- Positive Phase 3 CHAPTER-3 data could drive shares materially higher, with deucrictibant showing strong efficacy, significant U.S. adoption potential, roughly $2.5B sales potential if Phase 2 results are replicated, and peak global sales modeled around $1B for HAE attacks plus about $1.2B in U.S. prophylaxis sales. Here's what Citizens went on to say: https://x.com/Quantumup1/status/2087948836790509923?s=20
0 replies
JuggernautRaider Jul 23, 1:33 AM
$MIST i can get them if asked nicely 😉 check out my $TNXP and $KALV posts 💊
1 replies
JFais Jul 4, 2:28 PM
"Companies are bought, not sold (rule of thumb). Trick is to build a great company." - $KALV CEO
0 replies
JuggernautRaider Jul 1, 7:45 AM
$FBIO sold my shares. Good luck to the ROY (rest of y’all). This was no $KALV , $NUVB , or $TNXP . Fortress will struggle as long as FBIOP exists. Dilution and dividends: those two D’s kill biotech research companies 🪦
0 replies
JuggernautRaider Jun 25, 10:28 AM
$TNXP $NUVB $KALV $INSM Brother… the SEC is too slow. I invest long for a reason. Maybe i will start “playing” the stocks… i have a few I REALLY want to short 🤫
0 replies
JuggernautRaider Jun 21, 7:52 AM
$TNXP $NUVB $MIST $KALV do you work for free? No? Then… why should I?
3 replies